COST-EFFECTIVENESS OF TOFACITINIB FOR PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN CHINA

被引：0
|
作者：
Tian, L. [1 ]
Guo, Q. [2 ]
Xiong, X. [1 ]
Wang, L. [1 ]
Chen, Y. [3 ]
Dong, P. [3 ]
Ma, A. [1 ]
机构：
[1] China Pharmaceut Univ, Nanjing 32, Jiangsu, Peoples R China
[2] Renji Hosp, Shanghai, Peoples R China
[3] Pfizer Investment Co Ltd, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.1128
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMS18
引用
收藏
页码：S241 / S241
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China
    Tian, Lei
    Xiong, Xiaomo
    Guo, Qiang
    Chen, Yixi
    Wang, Luying
    Dong, Peng
    Ma, Aixia
    [J]. PHARMACOECONOMICS, 2020, 38 (12) : 1345 - 1358
  • [2] Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China
    Lei Tian
    Xiaomo Xiong
    Qiang Guo
    Yixi Chen
    Luying Wang
    Peng Dong
    Aixia Ma
    [J]. PharmacoEconomics, 2020, 38 : 1345 - 1358
  • [3] COST-EFFECTIVENESS OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN CHINA
    Wang, B. C.
    Chen, Y.
    Furnback, W.
    Wu, Q.
    Dong, P.
    [J]. VALUE IN HEALTH, 2018, 21 : S197 - S197
  • [4] Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea
    Lee, Min-Young
    Park, Sun-Kyeong
    Park, Sun-Young
    Byun, Ji-Hye
    Lee, Sang-Min
    Ko, Su-Kyoung
    Lee, Eui-Kyung
    [J]. CLINICAL THERAPEUTICS, 2015, 37 (08) : 1662 - 1676
  • [5] COST-EFFECTIVENESS OF TOFACITINIB COMPARED WITH ADALIMUMAB IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN IRAN
    Rezaei, S.
    Taheri, S.
    Tahmasebi, N.
    Peiravian, F.
    Yousefi, N.
    [J]. VALUE IN HEALTH, 2018, 21 : S295 - S296
  • [6] COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB IN COMBINATION WITH METHOTREXATE IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN GREECE
    Kourkoulas, N.
    Athanasakis, K.
    Boubouchairopoulou, N.
    Chouchouli, K.
    Kyriopoulos, J.
    [J]. VALUE IN HEALTH, 2018, 21 : S294 - S294
  • [7] Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan
    Chen, Der-Yuan
    Hsu, Ping-Ning
    Tang, Chao-Hsiun
    Claxton, Lindsay
    Valluri, Satish
    Gerber, Robert A.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (08) : 777 - 787
  • [8] Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis
    Tsao, Nicole W.
    Shojania, Kam
    Marra, Carlo A.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (01) : 9 - 18
  • [9] Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China
    Li, SiNi
    Li, JianHe
    Peng, LiuBao
    Li, YaMin
    Wan, XiaoMin
    [J]. RHEUMATOLOGY AND THERAPY, 2021, 8 (02) : 863 - 876
  • [10] Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China
    SiNi Li
    JianHe Li
    LiuBao Peng
    YaMin Li
    XiaoMin Wan
    [J]. Rheumatology and Therapy, 2021, 8 : 863 - 876
12345